HK Stock Market Move | CSTONE PHARMA-B(02616) opens nearly 5% higher. Multiple clinical key advancements related to CS2009 will be announced at the ASCO annual meeting in 2026.

CSTONE PHARMA-B(02616) opened nearly 5% higher, rising by 4.99% to 10.3 Hong Kong dollars with a trading volume of 3.2136 million Hong Kong dollars as of press time. On the news front, on April 22, CSTONE PHARMA-B announced that the company's independently developed PD-1/VEGF/CTLA-4 trispecific antibody CS2009 has made significant progress in multiple clinical trials, which will be officially disclosed through two posters at this year's American Society of Clinical Oncology (ASCO) annual meeting. The disclosed content will cover the phase I/II clinical trial data of CS2009 in non-small cell lung cancer (NSCLC) cohorts (first-line and later-line), as well as the phase I clinical extension follow-up results in patients with advanced solid tumors. The announcement stated that the global multicenter phase I/II clinical trial of CS2009 is rapidly progressing in Australia and China simultaneously. The Investigational New Drug (IND) application has also been approved in the United States, and the company is actively preparing to initiate the first phase III international multicenter clinical trial (MRCT) before the end of the year, focusing on indications such as NSCLC and colorectal cancer (CRC). As of now, more than 200 patients have been enrolled, and CS2009 has demonstrated excellent safety and tolerability in all dose groups evaluated, without the occurrence of severe toxicities commonly seen in combination therapies involving CTLA-4 and PD-(L)1, laying a solid clinical safety foundation for combination therapies with chemotherapy or antibody drug conjugates (ADC).